Compare BridgeBio Pharma Inc (BBIO) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Thomson Reuters Corp — how do they compare? BridgeBio Pharma Inc trades at $84.87 (market cap $16.46B), while Thomson Reuters Corp trades at $91.74 (market cap $39.67B). The key difference: Thomson Reuters Corp is far larger — about 2.4× BridgeBio Pharma Inc's market cap, and Thomson Reuters Corp pays a 2.86% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | TRI | |
|---|---|---|
Market Cap | $16.46B | $39.67B |
Sector | Health | Industrials |
52-Week High | $90.17 | $211.14 |
52-Week Low | $44.81 | $76.55 |
Enterprise Value | $18.02B | $41.62B |
Dividend Yield | — | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Thomson Reuters (TRI) trades at $94.29, up 5.18% today, showing strong momentum near resistance at $95. The stock maintains solid fundamentals with a 19.93% net margin and has beaten earnings estimates in two of the last three quarters. Recent developments include a joint venture with KKR and continued AI integration, positioning the company for growth in legal and professional markets.
The outlook is positive with a consensus price target of $129.96 implying 38% upside, supported by bullish analyst ratings (52% Buy). Key risks include execution of AI strategies and potential revenue pressures from market shifts. Institutional confidence remains high given stable cash flows and strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
